Idorsia AG is currently facing financial difficulties despite making progress in its drug development pipeline.
The company's share price has dropped significantly over the past year, causing concern among investors.
Idorsia is in need of fresh capital, but concrete deals have not yet materialized.
The recent approval of aprocitentan, an antihypertensive drug, is a positive development for the company and could generate revenue.
Idorsia will present new data on aprocitentan at an upcoming conference, which may boost investor confidence.
CEO Jean-Paul Clozel has outlined a plan to improve the company's financial situation, but the details are unclear.
Shareholders are urged to take action given the company's financial strain.
The success of Idorsia's drug marketing efforts will be crucial for its financial future.
The lack of immediate financial solutions raises concerns about the company's sustainability.
The market is closely watching Idorsia's next moves to restore investor confidence.